Postmastectomy Breast Reconstruction — ANY logic, coverage when any one met
Postmastectomy Breast Reconstruction
Skin and tissue substitutes are considered medically necessary for the treatment of postmastectomy breast reconstruction when ONE of the following criteria is met:
When there is insufficient tissue expander or implant coverage by the pectoralis major muscle and additional coverage is required.
When there are viable but compromised or thin postmastectomy skin flaps that are at risk of dehiscence or necrosis.
When the inframammary fold and lateral mammary folds have been undermined during mastectomy and reestablishment of these landmarks is needed.
Diabetic Foot Ulcers — ALL required criteria for coverage
Diabetic Foot Ulcers
Skin and tissue substitutes are considered medically necessary for the treatment of diabetic foot ulcers when ALL of the following criteria are met:
Physician documentation of medical management for clinically documented type 1 or type 2 diabetes.
Failure to achieve at least 50% ulcer area reduction with a minimum of 4 weeks of documented compliance with standard of care (SOC) treatment which includes but is not limited to mechanical offloading, infection control, limb elevation, debridement of necrotic tissue, management of systemic disease and medications, nutrition assessment, tissue perfusion and oxygenation, education regarding care of the foot, and appropriate footwear and counseling on tobacco use.
The wound is a non‑infected full thickness neuropathic diabetic foot ulcer of at least 1.0 cm2 in size due to clinically documented diabetic neuropathy.
The ulcer extends through the dermis but does not involve tendon, muscle, capsule, or bone exposure.
There is adequate arterial blood supply to support tissue growth.
The foot is free of Charcot arthropathy.
Chronic Venous Insufficiency Lower Extremity Ulcer — ALL required criteria
Chronic Venous Insufficiency Lower Extremity Ulcer
Skin and tissue substitutes are considered medically necessary for the treatment of chronic venous insufficiency ulcers when ALL of the following criteria are met:
Physician documentation of medical management for clinically documented chronic lower extremity venous insufficiency.
Failure to achieve at least 50% ulcer area reduction with a minimum of 4 weeks of documented compliance with standard of care (SOC) treatment which includes but is not limited to infection control, mechanical compression, limb elevation, debridement of necrotic tissue, management of systemic disease and medications, nutrition assessment, tissue perfusion and oxygenation, education regarding care, and counseling on tobacco use.
The wound is a non‑infected full thickness venous stasis ulcer of at least 1.0 cm2 in size due to clinically documented venous insufficiency.
The ulcer extends through the dermis but does not involve tendon, muscle, capsule, or bone exposure.
There is adequate arterial blood supply to support tissue growth.
Second- or Third-Degree Burns — ALL required criteria
Second‑ or Third‑Degree Burns
Skin and tissue substitutes are considered medically necessary for the treatment of second‑ and third‑degree burns when ALL of the following criteria are met:
The wound has been thoroughly debrided to remove necrotic tissue, bacteria, and other debris.
The wound is hemostatic with minimal bleeding to ensure optimal graft take.
The wound is free of infection or has a controlled infection as evidenced by negative cultures or significant reduction in bacterial load.
Healthy granulation tissue is present to support skin substitute take and integration.
Ophthalmologic Conditions (Amniotic membrane grafts) — ALL required criteria and prior conservative therapy
Ophthalmologic Conditions (Amniotic membrane grafts)
Human amniotic membrane (HAM) grafts with or without suture are considered medically necessary for the following ophthalmic indications when the specified conservative therapy requirements are met:
Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy.
Corneal ulcers and melts that do not respond to initial conservative therapy.
Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment.
Bullous keratopathy as a palliative measure in patients who are not candidates for curative treatment (e.g., endothelial or penetrating keratoplasty).
Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient.
Dystrophic Epidermolysis Bullosa — ALL required criteria
Dystrophic Epidermolysis Bullosa
The following product may be considered medically necessary for treatment of mitten‑hand deformity in dystrophic epidermolysis bullosa when provided in accordance with FDA Humanitarian Device Exemption (HDE) specifications and after failure of standard wound therapy:
ORCEL™ used in accordance with its HDE labeling for hand reconstruction surgery in dystrophic epidermolysis bullosa.
Initial Use Criteria — ALL required initial use elements
Initial Use Criteria
The following elements are required for initial use of skin and tissue substitute products (applies to covered indications unless otherwise specified):
Documentation of diagnosis and wound characteristics (size in cm2, depth, anatomic location, duration, and prior treatments).
Evidence of adherence to and failure of an appropriate period of standard of care (minimum 4 weeks unless indication specifies otherwise).
Evidence of adequate perfusion to support tissue growth (palpable pedal pulses or ABI > 0.70 as appropriate).
Wound bed preparation completed (debridement, control of infection/bioburden, removal of necrotic tissue) prior to application.
For diabetic foot ulcers: documentation of medical management of diabetes and HbA1c ≤ 12% unless otherwise justified.
Investigational / Not Reasonable and Necessary — list of investigational uses and exclusions
Investigational / Not Reasonable and Necessary — Uses and exclusions
All skin or soft tissue substitute products and uses not explicitly listed in the medically necessary sections above are considered investigational and not medically necessary due to insufficient evidence.
Use following Mohs micrographic surgery is considered investigational.
Surgical repair of hernias or parastomal reinforcement with these products is investigational.
Amniotic membrane, amniotic fluid, or other placental‑derived product injections/applications for musculoskeletal conditions (e.g., pain, tendon, joint conditions) are investigational — refer to appropriate MAC LCD for musculoskeletal indications.
Liquid or gel skin substitute products for ulcer treatment are not considered grafts and are not covered.
Use of skin substitutes for chronic wounds — ALL required criteria
Use of skin substitutes for chronic wounds — required criteria
Chronic, noninfected wound that has failed to respond to at least 4 weeks of standard of care (SOC) therapy.
Wound is full‑thickness but does not have exposed tendon, joint capsule, or bone.
Adequate arterial perfusion to support healing (palpable pulses or ABI > 0.70).
Wound bed adequately prepared (debridement, infection control, moisture balance) prior to application.
Documentation of wound size and progression (photographs and measurements) to demonstrate lack of adequate response to SOC.
Diabetic Foot Ulcers (DFU) — product‑specific RCT evidence and inclusion criteria (coverage summary)
Diabetic Foot Ulcers (Product‑specific RCT evidence and inclusion criteria)
For patients with diabetic lower‑extremity ulcers meeting the policy DFU criteria, randomized controlled trial evidence supports the use of specific products listed in the DFU medically necessary product list.
Product selection should align with the evidence base and documented inclusion criteria (e.g., noninfected, full‑thickness, size thresholds, prior SOC failure).
Venous Leg Ulcers (VLU) — inclusion criteria and adjunctive use to SOC
Venous Leg Ulcers (VLU) — inclusion criteria and adjunctive use to SOC
For patients with venous stasis lower‑extremity ulcers who meet the VLU clinical criteria, RCTs have demonstrated benefit for select products listed in the VLU covered product list.
Skin substitutes for VLU should be used as an adjunct to compression therapy and other SOC measures; they are not a substitute for compression.
Breast Reconstruction — coverage when used per surgical need and evidence
Breast Reconstruction — coverage when used per surgical need and evidence
For implant‑based breast reconstruction with inadequate native tissue coverage or compromised skin flaps, use of listed allogeneic acellular dermal matrices (ADMs) and other covered products may be considered medically necessary when criteria are met.
Providers should discuss potential benefits and risks with patients, consistent with FDA communications regarding ADM use in breast reconstruction.
Dystrophic Epidermolysis Bullosa — limited/conditional coverage summary
Dystrophic Epidermolysis Bullosa — limited/conditional coverage summary
OrCel® may be covered for HDE‑specified use (mitten‑hand deformity) when standard wound therapy has failed and treatment follows HDE labeling and documentation requirements.
Deep Dermal Burns — coverage when donor skin limited or per FDA‑labeled indications
Deep Dermal Burns — covered when donor skin limited or per FDA‑labeled indications
Epicel® is covered when used in accordance with its HDE for extensive full‑thickness burns lacking sufficient donor skin (e.g., ≥ 30% TBSA as specified).
Integra® and TransCyte® are covered for second‑ and third‑degree burns when the burn care criteria are met and as indicated by product labeling and evidence.
HAM ophthalmic indications — mixed evidence and indication-specific coverage notes
Ophthalmologic HAM indications — mixed evidence and indication‑specific coverage notes
Select HAM products are covered for the ophthalmic indications listed when prior conservative therapy has failed and the specific clinical criteria are met (see ophthalmologic criteria group).
HAM is investigational for ophthalmic uses not explicitly listed in the ophthalmologic criteria section.
Musculoskeletal — refer to separate MAC LCD (coverage routing)
Musculoskeletal — refer to separate MAC LCD (coverage routing)
Amniotic membrane, amniotic fluid, and other placental‑derived product injections or applications for musculoskeletal indications are considered investigational within this policy and are governed by the applicable MAC LCD for musculoskeletal indications.
Refer to the designated Local Coverage Determination for coverage rules, indications, and documentation requirements for non‑wound musculoskeletal uses.
Indication-specific coverage summaries — multiple indication-level summaries bundled
Indication‑specific coverage summaries — multiple indication‑level summaries bundled
Coverage decisions are indication specific: products listed as covered for a given indication are only approved for that indication.
Unlisted products or uses for a covered indication are investigational and not medically necessary.
Claims must include product HCPCS, CPT application code, and applicable ICD‑10 codes supporting site, severity, and indication.
Evidence summaries for listed products — per-product documented evidence stance (excerpt)
Evidence summaries for listed products — per‑product documented evidence stance (excerpt)
The policy references randomized controlled trials and systematic reviews where available and summarizes product‑specific evidence in Table 5 (evidence table).
Evidence sufficiency varies by indication and product; products listed as covered have sufficient evidence to support meaningful improvement in net health outcome for the specified indications when criteria are met.
Breast reconstruction following mastectomy — covered products criteria group
Breast reconstruction following mastectomy — covered products criteria group
Covered ADM and dermal matrix products for breast reconstruction are limited to those specifically listed in the breast reconstruction product table and require documentation of the clinical indications identified in the postmastectomy criteria group.
Claims using Q4100 for unspecified skin substitute must include product name, package size purchased, amount applied, and amount wasted in the claim narrative/remarks.
Breast reconstruction — coverage stance (summary statement)
Breast reconstruction — coverage stance (summary statement)
When surgical circumstances warrant additional soft tissue support or coverage and the listed criteria are met, covered ADM and related products may be considered medically necessary.
All other products and uses for breast reconstruction not explicitly listed are investigational and not medically necessary.
Diabetic foot ulcer — coverage stance (policy-level statement)
Diabetic foot ulcer — coverage stance (policy‑level statement)
Coverage for DFU is conditional on meeting the detailed clinical criteria (see DFU criteria group) and use of products listed in the DFU covered product table.
DFU claims must include appropriate HCPCS product codes, CPT application codes, and ICD‑10 codes (including L‑codes where applicable).
Venous insufficiency leg ulcer — coverage stance (policy-level statement)
Venous insufficiency leg ulcer — coverage stance (policy‑level statement)
Coverage for VLU is conditional on meeting clinical criteria and use of products listed in the VLU covered product table, with adjunctive compression and SOC measures documented.
VLU claims must include appropriate HCPCS product codes, CPT application codes, and ICD‑10 codes (including L‑codes where applicable).
Dystrophic Epidermolysis Bullosa — Coverage statement with required criteria
Dystrophic Epidermolysis Bullosa — Coverage statement with required criteria
OrCel® is covered only for the HDE‑specified indication (mitten‑hand deformity) with documentation that standard wound therapy has failed and HDE labeling followed.
Claims must include Q4100 with the required narrative details when applicable.
Second- and Third-degree Burns — Coverage statement with required criteria
Second‑ and Third‑Degree Burns — Coverage statement with required criteria
Epicel®, Integra®, and TransCyte® may be covered for second‑ and third‑degree burns when the burn care criteria are met and product labeling/HDE requirements (where applicable) are followed.
Claims must include appropriate HCPCS product codes, CPT application codes, and relevant burn ICD‑10 codes.
Ophthalmologic Conditions — Coverage statement with required criteria
Ophthalmologic Conditions — Coverage statement with required criteria
HAM products listed for ophthalmic indications are covered when the indication‑specific criteria and prior conservative therapy requirements are met and appropriate CPT codes (65778, 65779, etc.) are used. HAM for unlisted ophthalmic indications is investigational.
Venous Insufficiency Leg Ulcer — Coverage statement (detailed criteria)
Venous Insufficiency Leg Ulcer — Coverage statement (detailed criteria)
VLU coverage requires documented venous insufficiency, failure of at least 4 weeks of SOC including compression, wound size ≥ 1.0 cm2, full‑thickness noninfected ulcer without tendon/muscle/capsule/bone exposure, and adequate perfusion.
Covered products for VLU are limited to those listed in the VLU product table.
Investigational / Not Medically Necessary — explicit list of products not covered
Investigational / Not Medically Necessary — explicit list of products not covered
Any product or HCPCS code listed in the investigational product code lists and tables within this policy are considered investigational and not medically necessary for all indications unless explicitly listed as covered for a specific indication.
Unlisted codes submitted for non‑covered services addressed in this policy will be denied as not covered.
Investigational — insufficient evidence list and rationale
Investigational — insufficient evidence list and rationale
A large number of amniotic, placental‑derived, acellular, cellular, and matrix‑like products lack sufficient peer‑reviewed, high‑quality evidence to support clinical effectiveness. These are listed in the policy's investigational product tables (Q42xx–Q43xx, etc.).
Products without identified literature or with only case reports/limited studies are not considered medically necessary.
DFU/VLU coverage routing — policy history directing DFU/VLU to LCDs
DFU/VLU coverage routing — policy history directing DFU/VLU to LCDs
Policy history documents that DFU and VLU internal criteria were removed and routing to applicable Local Coverage Determinations (LCDs) or Local Coverage Articles (LCAs) may apply when CMS/MAC determinations are in effect.
Interim updates have alternately removed and reinstated internal DFU/VLU criteria based on MAC/LCD publication status; providers should follow the most current guidance referenced in the policy history.